In addition, these ADCs also displayed significant cytotoxicity against various tumor cells expressing HER2 with IC50 values ranging from 0.02 to 0.2 nM (Table 1), which is consistent with maleimide-based ADCs, as previously reported (Wang et al., 2017). Here, ERBB2 is linked to neoplasm.